Cynthia Timmers to Protein Kinase Inhibitors
This is a "connection" page, showing publications Cynthia Timmers has written about Protein Kinase Inhibitors.
Connection Strength
0.559
-
Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020 07 01; 26(13):3117-3125.
Score: 0.140
-
KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. J Natl Compr Canc Netw. 2019 05 01; 17(5):409-413.
Score: 0.131
-
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leuk Lymphoma. 2018 04; 59(4):1008-1011.
Score: 0.117
-
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities. Mol Cancer Ther. 2017 02; 16(2):344-356.
Score: 0.110
-
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 08; 5(4).
Score: 0.033
-
A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. Cancer Res. 2017 01 01; 77(1):153-163.
Score: 0.028